Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptotagmin-3 (SYT3) is a member of the synaptotagmin family of membrane proteins characterized by their ability to bind calcium ions and associate with synaptic vesicle trafficking. SYT3 functions as a high-affinity calcium sensor at presynaptic nerve terminals, where it plays a critical role in accelerating the replenishment of synaptic vesicles, thereby enabling reliable high-frequency synaptic transmission. In addition to its presynaptic roles, SYT3 also mediates the endocytosis of AMPA-type glutamate receptors in the postsynaptic compartment, participating in mechanisms of synaptic plasticity and memory processes, notably facilitating synaptic weakening and forgetting. Mutations or dysregulation of SYT3 have been implicated in neurodevelopmental disorders such as epilepsy and autism spectrum disorder. SYT3 is predicted to participate in calcium-dependent exocytosis, phospholipid and protein binding, and dendrite extension. No drugs are currently approved for targeting SYT3 directly, but its role in neurological disorders makes it a potential future therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptotagmin-3 (SYT3).